Medical tech company Masimo (NASDAQ: MASI) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 7.9% year on year to $370.9 million. The company expects the full year’s revenue to be around $1.52 billion, close to analysts’ estimates. Its non-GAAP profit of $1.33 per share was 9% above analysts’ consensus estimates.

Is now the time to buy MASI? Find out in our full research report (it’s free).

StockStory’s Take

Masimo’s second quarter saw a negative market reaction despite the company reporting revenue and non-GAAP profit above Wall Street’s expectations. Management attributed results to ongoing cost structure improvements and a realignment of the sales force to emphasize commercial execution. CEO Catherine Szyman described the margin expansion as a direct outcome of “effective cost structure actions taken last year,” coupled with strong consumables growth and operational discipline. While the company faced new tariff impacts and a cybersecurity incident, successful mitigation efforts and resilient service revenue supported the quarter’s performance.

Looking ahead, Masimo’s updated guidance reflects both optimism around continued cost containment and caution regarding external headwinds such as tariffs. Management emphasized that further mitigation actions are underway, with CFO Micah Young stating, “Our updated EPS guidance now exceeds our original projections provided at the beginning of the year before the tariff situation had even started.” Key growth initiatives include expanding market share in advanced monitoring segments and launching next-generation wearable and intelligent monitoring technologies. Leadership changes are expected to further strengthen execution in global markets.

Key Insights from Management’s Remarks

Management pointed to sales force realignment, leadership expansion, and targeted cost actions as key drivers of margin gains and future growth, while also addressing tariff mitigation and operational resilience.

• Sales force realignment: The U.S. sales team transitioned from product specialty groups to regionally led teams, aiming to leverage strength in pulse oximetry to boost market share in adjacent categories like capnography and brain monitoring. Management expects this shift to drive higher pull-through across advanced monitoring products over time.
• Leadership expansion: Several new executive hires—including a Chief Commercial Officer, Chief Marketing and Strategy Officer, and regional president for Japan and Asia Pacific—were made to enhance commercial excellence and accelerate international growth. CEO Catherine Szyman highlighted these appointments as foundational for the next phase of growth.
• Operational improvements: Cost structure actions implemented in the previous year contributed to a 600-basis-point increase in operating margin, aided by ongoing initiatives to optimize manufacturing and supply chains.
• Tariff mitigation efforts: The company’s operations and finance teams reduced expected tariff expenses by over 50% compared to original estimates through supply chain adjustments and administrative measures for product exemptions. This significantly offset the impact of new tariffs on margins.
• Resilience to external shocks: The team managed a cybersecurity incident with minimal disruption, incurring nonrecurring expenses but maintaining core business operations and order fulfillment, which management noted as evidence of organizational resilience.

Drivers of Future Performance

Masimo’s outlook is shaped by continued cost controls, strategic investments in technology, and efforts to navigate external risks such as tariffs and market demand shifts.

• Tariff mitigation and supply chain: Management is pursuing further medium-term tariff mitigation, including qualifying more products for trade exemptions and optimizing sourcing. CFO Micah Young reiterated that ongoing efforts could reduce the tariff burden by another 100 to 110 basis points, but acknowledged that the situation remains fluid and will require persistent focus.
• Product innovation and market expansion: The upcoming launch of next-generation intelligent monitors and wearables is expected to bolster long-term growth. The company is piloting new AI-based algorithms and hemodynamic monitoring products, aiming to expand presence in markets like capnography and brain monitoring where current share remains below 20%.
• Commercial execution and leadership: The expanded executive team, combined with the realigned sales force, is tasked with driving commercial excellence across global markets. Management expects these changes to gradually increase adoption of advanced monitoring solutions, especially as new products are rolled out and international operations scale up.

Catalysts in Upcoming Quarters

In the coming quarters, our team will be monitoring (1) the pace of adoption for new intelligent monitoring and wearable technologies, (2) the effectiveness of ongoing tariff mitigation efforts and their impact on margins, and (3) execution of the expanded commercial strategy, especially in underpenetrated markets like Asia Pacific. Progress on the Philips partnership and rollout of next-generation hemodynamic monitors will also be key indicators of strategic progress.

Masimo currently trades at $149.01, down from $164.32 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.